Background: Hyaluronic acid (HA) fillers are sometimes mixed with lidocaine to mitigate pain. Whether the addition of epinephrine to lidocaine provides greater benefits in bruising and pain has not been fully reported. Objectives: The investigators explored the severity of bruising and pain in patients treated with the cohesive polydensified matrix HA (CPMHA) in 3 different preparations: CPMHA (Belotero Balance [BEL]), CPMHA with lidocaine (BEL-L), and CPMHA with lidocaine and epinephrine (BEL-LE). Methods: In a blinded, split-face, 14-day study, 30 patients were divided into groups of 10. One group received 1.0 mL BEL in the perioral lines on 1 side and 1.0 mL of BEL-LE on the other side. A second group received 1.0 mL of BEL on 1 side and 1.0 mL of BEL-L on the other side. The third group received 1.0 mL of BEL-L on 1 side and 1.0 mL of BEL-LE on the other side. Over 3 visits, the treating investigator, the patients, and a blinded investigator rated the bruising. Results: Bruising occurred in each treatment group by day 1 but resolved for half of the patients by day 7 and for all patients by day 14. Split-face comparison did not reveal a significant difference in pain and bruising scores among the 3 preparations. Conclusions: No significant difference was found in bruising or pain in patients treated with BEL, BEL-L, and BEL-LE. Studies with a considerably larger sample size are warranted to determine statistically significant and clinically meaningful differences between and among the various formulations.
correction of moderate-to-severe facial wrinkles and folds, such as NLFs. 6 Prior studies have confirmed the safety and effectiveness of BEL in treating NLFs, oral commissures, and other areas of the face. [7] [8] [9] [10] [11] [12] In 2007, an article was published citing a novel way of mixing the soft-tissue filler calcium hydroxylapatite (CaHA) with lidocaine to reduce pain during injection of the hand. 13 In 2009, the Food and Drug Administration (FDA) sanctioned mixing lidocaine with CaHA. 14, 15 Physicians quickly surmised that lidocaine with CaHA to mitigate pain could perhaps be extended to the addition of lidocaine to hyaluronic acids (HA). [16] [17] [18] Lidocaine acts primarily by inhibiting sodium influx through sodium-specific ion channels in the neuronal cell membrane (specifically named the voltage-gated sodium channels). The receptor site for the lidocaine is believed to be located at the cytoplasmic (inner) portion of the sodium channels. Lidocaine passes through the cell membrane readily in its nonionized form. Once it enters the cell membrane it becomes ionized by becoming protonated and attaches to the receptor on the sodium ion channels. When the influx of sodium is interrupted, an action potential cannot arise, and signal conduction is inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel.
Once inside the cell, the local anesthetic is in equilibrium with the formation of the protonated (ionized) form, which does not readily pass back out of the cell. This is referred to as "ion-trapping." In the protonated form, the molecule binds to the local anesthetic binding site on the inside of the ion channel near the cytoplasmic end. Most local anesthetics work on the internal surface of the membrane, ie, the drug has to penetrate the cell membrane, an action best achieved in the nonionized form. [19] [20] [21] [22] [23] In clinical practice, many physicians are now mixing HA with lidocaine-with or without epinephrine (for vasoconstriction) -to mitigate bruising. [24] [25] [26] We were interested in the effect that different preparations of BEL would have on severity of bruising. We were also interested in severity of pain, comparing lidocaine alone to lidocaine/epinephrine preparations. Thirty patients were enrolled in our study to evaluate the severity of pain and bruising with 3 different mixing preparations: 1 with BEL; 1 with BEL and lidocaine; and 1 with BEL, lidocaine, and epinephrine. Split-face comparisons were used to eliminate the confounding effect of inter-patient pain sensitivity and bruising. Therefore the pain and bruising on one side of the lip was compared to the contralateral side in the same patient.
In this blinded, split-face study, we sought to assess severities of bruising and pain across 14 days in 3 different mixing protocol preparations: BEL alone (BEL), BEL with lidocaine (BEL-L), and BEL with lidocaine and epinephrine (BEL-LE).
METHODS
Beginning with screening and enrollment in July 2013 and completing analysis in November 2013, this was a randomized, blinded, and split-face study of 30 patients from 1 United States (US) investigational center. The study was conducted in accordance with the guidelines set forth in the Declaration of Helsinki. Patients underwent superficial to mid-dermal injection of 3 different mixing preparations of BEL (BEL, BEL-L, and BEL-LE) for correction of lip wrinkles.
Study Population

Inclusion Criteria
Individuals were eligible for inclusion in the study if they were men or nonpregnant, nonbreastfeeding women, 18 to 75 years of age, and seeking treatment for correction of perioral lines. Those eligible manifested pretreatment perioral line severity of mild to severe using the validated Merz wrinkle-severity scale of lips at rest. 8 Patients had the ability to understand and comply with the requirements of the study, were willing to abstain from exclusionary procedures for the duration of the study, were willing to give written informed consent to participate in the study, and (women only) were willing to use an acceptable form of birth control throughout the study.
Exclusion Criteria
Patients who were not eligible for the study were associated with one or more of the following conditions: active or chronic skin disease, inflammation or related conditions in the perioral area, recent procedures based on active dermal response (eg, laser or chemical peeling procedures) on the perioral area within 4 weeks prior to study treatment, anticoagulant therapy, previously experienced unanticipated adverse effects when treated with HA products, severe allergies manifested by a history of anaphylaxis or a history or presence of multiple severe allergies, a history of allergies to gram-positive bacterial proteins, any condition which-in the opinion of the investigator-made the patient unsuitable for inclusion, cancerous or precancerous lesions in the area to be treated, and participation in any interventional clinical trial within 30 days prior to treatment.
Screening
Screening and treatment were performed at the first visit. Following study approval by the institutional review board (Aspire IRB, Santee, California), 30 women were screened; they were then counseled on the risks and benefits of the procedure. Screening included recording of medical history, obtaining informed consent, and assessing eligibility criteria. After informed consent was obtained, the patients were enrolled.
At screening, the investigator and the patients used a validated Merz 5-point Wrinkle Severity Scale of lip lines at rest to evaluate the visual appearance of the Lip Wrinkle lines independently for study inclusion. 8 At rest Scale Scores had to range from mild (1) to severe (3) for the selected lip lines to be eligible for enrollment. Standard photographs (facing frontally) were taken to document pretreatment condition using a Canfield Camera (Canfield Clinical Services, Passaic, NJ: Canon EF-S 60 mm f2.8 macro lens, with a face device zido cart and chin rest).
Treatment
Treatment was administered via 30-G needle at baseline (day 0) for optimal correction of lip wrinkles, defined as the best aesthetic result that could be obtained for the lip line of an individual study participant using 1 mL of filler per side. One mL was used on each side for a total of 2 mL across all patients. To help keep the study as blinded as possible, all syringes were premixed by the clinical research coordinator in a location removed from the treatment area. In addition, syringes were blinded at the time of injection, with an assistant overseeing the procedure to make certain that the appropriate mixtures for each patient were provided to the investigator during the time of injection. The BEL syringe (without any concentration of lidocaine or lidocaine epinephrine) was similarly transferred back and forth 20 times using an empty syringe in order to look comparable to the BEL-L and BEL-LE syringes.
The volumes in each of the syringes were adjusted to 1 mL in total. The BEL syringe consisted solely of 1.0 mL of hyaluronic acid; the BEL-L consisted of 0.3 mL of lidocaine HCL 1% added to BEL; and the BEL-LE syringe consisted of 0.3 mL of lidocaine HCL 1% and epinephrine 1:100,000 added to BEL (Hospira, Inc., Lake Forest, IL). The syringes were marked with "L" for left and "R" for right, based on preinjection randomization. All injections were performed in the superficial dermis with serial punctures and linear threading techniques. The entire 1-mL syringe of 1 mixture was injected on 1 side of the upper and lower lip followed by injection of 1 mL of a different mixture on the contralateral side. Consequently, each patient was injected with a total of 2 mL of product, 1 mL on each side. The volume of lidocaine was 3 mg in the BEL-L syringes, and 3 mg, along with 3 mcg of epinephrine, in the BEL-LE syringes.
As part of the randomization process, sealed envelopes with equal numbers of the treatment arms were prepared prior to recruitment. A staff member, independent of treatment and recruitment, shuffled the envelopes. The envelopes were kept in a locked cabinet and the envelope on top was opened only after a patient qualified for enrollment. Three cohorts, each composed of 10 patients, were randomly assigned to receive the following injection mixtures. Immediately postinjection and postpain evaluation, the areas treated were gently massaged with the gloved thumb and index finger to assure there were no palpable bumps.
Evaluation
Adverse Events
The investigator evaluated all local and systemic adverse events at all visits, both through physical inspection of the patients and through anecdotal patient case histories.
Bruising
Assessment of bruising was performed on day 0 pretreatment, then at posttreatment day1, day 7 (±2 days) and day 14 (±2 days) by the blinded investigator (AM), using a 4-point nonvalidated scale, in which 0 represents "no visible bruising" and 3 represents "severe" bruising ( Table 1) . The blinded investigator, who is the lead author of the study, is a board-certified facial plastic surgeon with current and past involvement in several FDA studies evaluating dermal fillers. The patients (also blinded) used the bruising scale at the time of each follow-up visit to determine severity of bruising posttreatment. Using the same scale, at the end of the study the blinded evaluator (AS) reviewed and scored the patient photographs that were taken in random order on each visit (day 0, 1, 7, and 14). The blinded evaluator is a boardcertified dermatologist with experience in injections and clinical research.
Pain
Patients were asked to score their pain levels immediately after completion of first-side treatment of the perioral lines. As soon as pain had been assessed, the contralateral side was treated, followed again by pain assessment immediately postinjection. Patients completed a nonvalidated Visual Analogue Scale, rating their pain in severity range from "no pain" to "agonizing pain." (See Figure 2) .
Statistical Analysis
Descriptive statistics were used to quantify bruising and pain numerically. The study was not powered sufficiently to determine either the presence of absence of statistical significance (see Discussion).
RESULTS
Investigators assessed safety, bruising, and pain severity in this blinded, randomized, split-face study. Age range of the patients, all women, was 41 years to 72 years, with a mean of 52.6 years. No patients were lost to follow-up. 
Safety
No severe adverse events were reported by the patients or observed either by the investigator or the patient at any of the time points of the study. Bruising and pain were the most frequent events, reported by all patients. No lumps or nodules were reported either by the investigator or by the patient.
Bruising
Evaluation of bruising severity was made on day 0 at pretreatment and posttreatment, day 1, day 7, and day 14. Bruising was most pronounced on day 1, then declined by more than half by day 7, and had resolved in all patients by day 14. Bruising reported for each mixture is shown in Tables 2-4. Bruising scores for day 0 and day 14 were 0 for each patient and consequently are not shown; bruising scores for days 1 and 7 are shown for each of the preparations. Regardless of the mixture, the evaluations by the blinded treating physician investigator (PI), blinded patients, and blinded evaluator were similar across cohorts. Figure 3 shows the aggregate scores by cohort. Figure 4 shows representative bruising on day 0, day 1, day 7, and day 14. Figures 5-7 show day 1 and day 7 series of images of 3 patients treated with either BEL-LE and BEL, or BEL-L and BEL, or BEL-L and BEL-LE.
Pain
Evaluation of pain was recorded by patients immediately postinjection in 1 side of the face and then immediately post injection in the other side of the face. Table 5 shows the patients' pain scores for each of the 3 cohorts. Figure 8 illustrates the aggregate pain scores for each of the 3 preparations.
DISCUSSION
We sought to strengthen the validity of the comparisons reported here through use of a split-face, randomized, blinded study design. The different preparations to be injected were delivered in identical syringes, so that only the assistant knew which syringe contained which preparation. Given our awareness about the small size of the treatment cohorts, we deliberately injected 1 mL of blinded preparations into each side to control as much as possible for preparation and/or injector bias toward 1 of the 3 preparations and against the other 2. In regard to the preparations, investigators attempted to simulate the volume dilution effect of the lidocaine (and epinephrine) through volumes of each that the investigators use in clinical practice. The addition of a very small amount of sterile water to the BEL syringe to control for minor volume differences was considered but discounted since the investigators wanted to mimic the clinical use of the HA as much as possible.
Lack of validation of a posttreatment-bruising scale warrants comment. Although the bruising scale used in this study has not been validated, it should be noted that the ratings by the patients do not differ widely from the ratings by the 2 evaluators. We believe that the similarities in rating scores by the blinded evaluator, the blinded treating investigator, and the patients support the reliability of the scales as a measure of bruising. Figure 3 also shows the narrow range of bruising scores across cohorts. We are heartened by the rating similarities across all evaluator segments but are hard-pressed to elaborate on inter-rater consistency, given the sample size.
Not unlike the results found with evaluation of bruising, the differences in perceived pain were similar across all 3 cohorts in the study. This supports the fact that the effect of lidocaine is not instantaneous; some time is required for the lidocaine to enter the neuronal membrane where it asserts its effect. In addition, although we planned for control of bruising, we could not plan for bias of pain on the part of the patients. One effort to control for pain bias was to avoid the use of topical anesthetic products, with their inherent confounding variations (eg, different types of anesthetics, amount used per square inch, duration of application, and varying absorption rates). Without topical anesthesic and without awareness of which preparation was in which syringe, the patients rated pain in each side. The patients knew they were part of a study; whether that knowledge influenced them to lower (or increase) their assessment of pain cannot be determined. In addition, cannulas were not used because of concerns about depth of injection of the dermal fillers in the superficial perioral lines. All scores by physician investigator (PI), blinded evaluator, and patients were 0 on day 0 and day 14. PI scores on day 1 were 1 (R, right) and 1 (L, left) and 0 (R) and 0 (L) on day 7. Blinded evaluator scores on day 1 were 1 (R) and 2 (L) and 0 (R) and 0 (L) on day 7. Patient scores on day 1 were 1 (R) and 1 (L) and 0 (R) and 0 (L) on day 7.
Consequently, the role of pain reduction through the use of cannulas was not explored.
The finding of little difference in pain between BEL and BEL-L is unusual and, to no small extent, contradictory to other publications and experiences of hyaluronic acids injected with lidocaine. 18, [27] [28] [29] [30] [31] [32] [33] [34] We have always used lidocaine in our clinical practice for ease of injection and reduction of pain. The limited benefit of lidocaine in this investigatorinitiated small study could be partly due to the treating investigator not waiting long enough for the lidocaine to fully take effect as well as to the increased pain in 1 area of the face (eg, the perioral lines) compared to another area (eg, the NLFs). In addition, we confined our evaluation of pain to the superficial dermis. Whether pain results in the deep dermis would be different cannot be determined from this study. Our study was designed to measure perioral pain only immediately posttreatment and bruising over a period of 2 weeks. To that end, we assessed pain 1 time Figure 7 . This 41-year-old woman received 1.0 mL of BEL-L (cohesive polydensified matrix hyaluronic acid with lidocaine) in her right perioral area and 1.0 mL of BEL-LE (BEL-L with epinephrine) in her left perioral area. Day 1 (A) and day 7 (B) images were obtained. All scores by physician investigator (PI), blinded evaluator, and patient were 0 on day 0 and day 14. PI scores on day 1 were 2 (R, right) and 2 (L, left) and 0 (R) and 0 (L) on day 7. Blinded evaluators scores on day 1 were 2 (R) and 2 (L) and 1 (R) and 1 (L) on day 7. Patient scores on day 1 were 1 (R) and 2 (L) and 1 (R) and 1 (L) on day 7. Figure 6 . This 61-year-old woman received 1.0 mL of BEL-L (cohesive polydensified matrix hyaluronic acid with lidocaine) in her right perioral area and 1.0 mL of BEL in her left perioral area. Day 1 (A) and day 7 (B) images were obtained. All scores by physician investigator (PI), blinded evaluator, and patients were 0 on day 0 and day 14. PI scores on day 1 were 3 (R, right) and 2 (L, left) and 0 (R) and 0 (L) on day 7. Blinded evaluator scores on day 1 were 2 (R) and 3 (L) and 0 (R) and 0 (L) on day 7. Patient scores on day 1 were 3 (R) and 2 (L) and 0 (R) and 0 (L) on day 7. and bruising 4 times. In a study published several years ago, investigators asked 45 NLF-injected patients to rate their pain levels at 5 time intervals over an hour. 31 Whether the pain scores in our study would have more closely mirrored beneficial findings of lidocaine use in the earlier study is not known.
At the present time, many injectors continue to mix the dermal fillers they use with lidocaine and at times with epinephrine as well to decrease bruising. We acknowledge the inherent limitations associated with small sample populations and have tried to anticipate these in our attention to randomization and blinding. Powering the study for the possibility of statistical difference remains a concern. Our study lacked the power to determine statistical differences across the cohorts. This is an investigator-initiated study of 30 patients at 1 study site; developing a patient population sufficient for statistical significance is beyond the scope of a study that, from the outset, was intended to be a source for hypothesis generating rather than providing any definitive conclusions.
We believe this study could be helpful in shaping the protocols for larger studies of pain and bruising postinjection of dermal fillers that would either invalidate or support the tentative findings reported here. In this study, the effect of the differences in preparations is difficult to quantify due to sample size; larger population studies may be required to demonstrate statistical, as well as clinically meaningful, differences.
CONCLUSIONS
Based on our study in the correction of lip lines, we observed no significant differences in pain or bruising when lidocaine or lidocaine and epinephrine were added to BEL. Future studies may explore many different variables such as different facial regions and different concentrations of lidocaine.
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